Garetosmab — Safety, Research, Risks & Legal Status

Not medical advice. Garetosmab is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	REGN2477; garetosmab (INN)
Category	Peptide (research chemical)
Developer	Regeneron Pharmaceuticals (development code REGN2477); possible Sanofi partnership
Drug class	Fully human IgG4 anti-Activin A monoclonal antibody (VelocImmune platform)
Primary indication	Fibrodysplasia Ossificans Progressiva (FOP) - ultra-rare progressive heterotopic ossification disorder
Regulatory status (US, mid-2026)	BLA under FDA Priority Review; PDUFA target action date August 2026; Orphan Drug + Fast Track designations
Phase 3 primary efficacy (OPTIMA)	94% reduction new bone lesions (3 mg/kg) and 90% (10 mg/kg) vs baseline; >99% lesion volume reduction
Notable safety signal	5 deaths (11.4%) in Phase 2 open-label extension; causality considered unlikely but not excluded; also epistaxis (~50%) and madarosis (~25%)
US legal status	Not approved in the United States as of mid-2026. A Biologics License Application (BLA) was accepted by the FDA under Priority Review in February 2026, with a target action date of August 2026. Holds Orphan Drug designation (US and EU) and Fast Track designation (granted 2017). Eligible for expanded access on a compassionate-use basis. Not legally available for general consumer purchase or personal use; classified as an investigational biologic.

What is Garetosmab?

Garetosmab (development code REGN2477) is a fully human IgG4 monoclonal antibody developed by Regeneron Pharmaceuticals using their VelocImmune platform. It targets and neutralizes Activin A, a member of the TGF-beta superfamily of signaling proteins. Its primary investigational indication is Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare, severely disabling genetic disorder in which soft tissues - muscles, tendons, ligaments - progressively ossify into heterotopic bone following injury or spontaneous flare-ups. FOP is caused by a gain-of-function mutation in the ACVR1 receptor; Activin A aberrantly activates this mutant receptor in FOP patients, driving pathologic bone formation. Garetosmab is distinct from myostatin inhibitors and does not directly target ACVR1; rather, it neutralizes the Activin A ligand upstream of receptor engagement.

How it works

Garetosmab binds Activin A with high affinity and prevents it from engaging the ACVR1 (ALK2) receptor. In individuals carrying the FOP-associated ACVR1 R206H gain-of-function mutation, Activin A - which is normally a non-activating ligand for wild-type ACVR1 - paradoxically activates the mutant receptor and triggers the SMAD1/5/8 signaling cascade responsible for heterotopic ossification (HO). By sequestering circulating Activin A, garetosmab aims to interrupt this aberrant signaling upstream, reducing or preventing new heterotopic bone lesion formation. Activin A inhibition is mechanistically separate from myostatin pathway blockade, though both ligands belong to the broader TGF-beta superfamily.

Background & history

Regeneron initiated Phase 1 pharmacokinetics and pharmacodynamics studies for REGN2477, with results published in the Journal of Clinical Pharmacology (PubMed: REGN2477 pharmacokinetics phase 1). Fast Track designation was granted by the FDA in 2017. The Phase 2 randomized double-blind placebo-controlled trial (LUMINA-1, 44 adult FOP patients) was completed and published in Nature Medicine in September 2023 (PubMed: garetosmab fibrodysplasia ossificans progressiva Nature Medicine 2023). Although the primary endpoint (PET-CT lesion activity reduction) was not statistically met (P=0.0741), a key crossover analysis showed 0% new lesions on active drug versus 40.9% during placebo periods (P=0.0027), supporting advancement. The Phase 3 OPTIMA trial in 63 adults reported positive results in September 2025, meeting its primary endpoint. A BLA was submitted to the FDA and accepted under Priority Review in February 2026, with a PDUFA target action date in August 2026. A Phase 3 pediatric trial (OPTIMA 2) is planned to begin in 2026.

What the research says

Human clinical data exist at Phase 2 and Phase 3 levels, though the total studied population remains small given the rarity of FOP.

Phase 2 (LUMINA-1): Randomized, double-blind, placebo-controlled trial in 44 adults with FOP. Primary endpoint (reduction in PET-CT heterotopic ossification lesion activity) was not statistically met in the primary analysis (P=0.0741). However, during a crossover period, 0% of garetosmab-treated participants developed new lesions versus 40.9% during placebo periods (P=0.0027). Published in Nature Medicine, September 2023 (PubMed: garetosmab LUMINA-1 FOP 2023). Five deaths occurred in the open-label extension period (11.4% of 44 participants); causality relative to drug was considered unlikely by investigators but was not definitively excluded, and the benefit-risk profile was subject to continued evaluation.

Phase 3 (OPTIMA): 63 adult FOP patients, 56-week treatment duration. Results reported September 2025. Primary endpoint met: the 3 mg/kg dose arm demonstrated approximately 94% reduction in new heterotopic bone lesions; the 10 mg/kg arm approximately 90% reduction. Greater than 99% reduction in total lesion volume was reported. These represent the strongest efficacy data available for any FOP therapeutic candidate to date.

Investigational interest in obesity/sarcopenia has been noted - specifically the potential to preserve skeletal muscle mass in patients losing weight on GLP-1 receptor agonists - but no human trial results in that indication are available as of mid-2026.

Reported effects

Reduction of new heterotopic ossification (ectopic bone) lesion formation in FOP patients - demonstrated in Phase 2 crossover analysis and Phase 3 primary endpoint
Reduction in total heterotopic bone lesion volume - Phase 3 data show greater than 99% reduction
Neutralization of circulating Activin A, reducing aberrant ACVR1 signaling in FOP-mutant tissue
Potential stabilization of disease course in an otherwise progressive and irreversible condition - investigational
Possible skeletal muscle preservation during GLP-1-mediated weight loss - investigational only, no human trial data in this indication

Dosing & administration (informational)

Published clinical trial literature has evaluated doses of 3 mg/kg and 10 mg/kg administered intravenously on a regular schedule; specific dosing intervals are described in trial protocols registered at ClinicalTrials.gov (search: OPTIMA garetosmab FOP). Both doses demonstrated efficacy in Phase 3, with 3 mg/kg showing slightly higher new-lesion reduction. These are investigational dosing parameters from trial protocols and are provided here for informational reference only. No dosing protocol should be derived from this entry. Consult a qualified physician or the prescribing information upon potential approval for any clinical guidance.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Epistaxis (nosebleeds): occurred in approximately 50% of garetosmab-treated patients versus 16.7% placebo in Phase 2; attributed to Activin A's role in vascular integrity
Madarosis (loss of eyelashes and eyebrows): 25% in Phase 2 active arm versus 0% placebo; mechanism thought to involve Activin A's role in hair follicle cycling
Skin and soft tissue infections: folliculitis, carbuncles, furuncles, and skin abscesses reported
Infusion-related reactions including headache, fatigue, nausea, and mild fever in approximately 9-25% of participants
Five deaths occurred in the Phase 2 open-label extension period (5 of 44 participants, 11.4%); investigators considered causal relationship to study drug unlikely, but causality was not fully excluded; benefit-risk evaluation continued in Phase 3
Most adverse events in Phase 2 were mild to moderate, manageable, and resolved without intervention; no dose-limiting toxicities were identified
Activin A inhibition carries theoretical risks related to its physiological roles in reproduction, erythropoiesis, and immune regulation; full long-term safety profile is still being characterized

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
p
u
b
l
i
c
l
y
r
e
p
o
r
t
e
d
a
s
o
f
m
i
d
-
2
0
2
6
.
A
s
a
m
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
,
g
a
r
e
t
o
s
m
a
b
i
s
u
n
l
i
k
e
l
y
t
o
i
n
t
e
r
a
c
t
w
i
t
h
c
y
t
o
c
h
r
o
m
e
P
4
5
0
e
n
z
y
m
e
s
.
T
h
e
o
r
e
t
i
c
a
l
l
y
,
c
o
n
c
u
r
r
e
n
t
u
s
e
o
f
o
t
h
e
r
i
m
m
u
n
o
s
u
p
p
r
e
s
s
a
n
t
s
c
o
u
l
d
a
m
p
l
i
f
y
i
n
f
e
c
t
i
o
n
r
i
s
k
g
i
v
e
n
o
b
s
e
r
v
e
d
s
k
i
n
/
s
o
f
t
t
i
s
s
u
e
i
n
f
e
c
t
i
o
n
s
i
g
n
a
l
s
.
A
c
t
i
v
i
n
A
p
l
a
y
s
r
o
l
e
s
i
n
e
r
y
t
h
r
o
p
o
i
e
s
i
s
a
n
d
r
e
p
r
o
d
u
c
t
i
v
e
e
n
d
o
c
r
i
n
o
l
o
g
y
;
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
a
g
e
n
t
s
a
f
f
e
c
t
i
n
g
t
h
e
s
e
s
y
s
t
e
m
s
a
r
e
u
n
s
t
u
d
i
e
d
.
C
l
i
n
i
c
a
l
p
h
a
r
m
a
c
o
l
o
g
y
d
a
t
a
f
r
o
m
P
h
a
s
e
1
a
n
d
L
U
M
I
N
A
-
1
a
r
e
a
v
a
i
l
a
b
l
e
i
n
t
h
e
J
o
u
r
n
a
l
o
f
C
l
i
n
i
c
a
l
P
h
a
r
m
a
c
o
l
o
g
y
(
P
u
b
M
e
d
:
R
E
G
N
2
4
7
7
c
l
i
n
i
c
a
l
p
h
a
r
m
a
c
o
l
o
g
y
L
U
M
I
N
A
-
1
2
0
2
4
)
.

Who should avoid it

Use outside a supervised clinical trial or FDA-authorized expanded access program
Self-administration or non-medical-setting use - this is an IV biologic requiring clinical monitoring
Assumption of safety based on Phase 2 data alone given the unresolved Phase 2 mortality signal
Use in pregnancy or in individuals planning pregnancy without specialized consultation - Activin A has known roles in reproductive biology
Procurement from any non-Regeneron or non-clinical-trial source

How it is commonly combined

No stacking data exist. Garetosmab is under investigation as a monotherapy for FOP. Combinatorial use with other investigational FOP agents (e.g., palovarotene, a retinoic acid receptor gamma agonist separately approved for FOP in Canada) has not been studied in human trials. Any combination in an investigational context would require independent regulatory and ethics approval.

Legal & regulatory. Not approved in the United States as of mid-2026. A Biologics License Application (BLA) was accepted by the FDA under Priority Review in February 2026, with a target action date of August 2026. Holds Orphan Drug designation (US and EU) and Fast Track designation (granted 2017). Eligible for expanded access on a compassionate-use basis. Not legally available for general consumer purchase or personal use; classified as an investigational biologic.

Quality & harm reduction

Safer, legal alternative we recommend

Creatine Supreme. For supporting muscle mass and strength, creatine monohydrate is the most evidence-backed legal option, with decades of safety data - ours ships from the Peptropix line.

See our recommended pick

Find Garetosmab →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What is garetosmab and why is it significant for FOP?

Garetosmab is an investigational monoclonal antibody that neutralizes Activin A, a protein that aberrantly activates the mutant ACVR1 receptor in FOP patients and drives progressive heterotopic ossification. FOP is an extremely rare genetic disorder with no currently FDA-approved treatment in the US as of early 2026, making any effective disease-modifying agent highly significant. Phase 3 data showed approximately 94% reduction in new bone lesions at the 3 mg/kg dose.

Has garetosmab been approved by the FDA?

Not as of mid-2026. A Biologics License Application was submitted by Regeneron and accepted by the FDA under Priority Review in February 2026. The target action date is August 2026. Garetosmab is not yet approved, though it may be accessible through an expanded access (compassionate use) program for eligible FOP patients.

What were the safety concerns identified in clinical trials?

The most notable safety signals from Phase 2 were epistaxis (nosebleeds, approximately 50% of treated patients), madarosis (loss of eyelashes and eyebrows, 25%), and skin infections including folliculitis and skin abscesses. Infusion-related reactions were also reported. Critically, five deaths occurred in the Phase 2 open-label extension period; investigators considered causality to the drug unlikely but it was not definitively ruled out. The overall benefit-risk profile was further evaluated in Phase 3. Most other adverse events were described as mild to moderate and self-resolving.

Is garetosmab available to purchase or use outside of a clinical trial?

No. Garetosmab is an investigational biologic produced solely by Regeneron Pharmaceuticals and is only available through sponsored clinical trials or potentially through a formal expanded access program. It is not commercially sold, and no legitimate research-chemical or consumer market exists for it. Any product marketed as garetosmab outside these channels should be considered unverified.

Is garetosmab being studied for anything other than FOP?

There is reported investigational interest in using Activin A inhibition to preserve skeletal muscle mass in patients undergoing significant weight loss on GLP-1 receptor agonist therapy. However, as of mid-2026 no human trial results in that indication have been published. All existing efficacy data are specific to FOP.

What dosing protocol should I follow if I have access to garetosmab?

This entry does not provide dosing guidance. Garetosmab is an intravenous biologic that in clinical trials was administered under close medical supervision with monitoring for adverse events. Dosing parameters from published trial protocols are available via ClinicalTrials.gov (search: OPTIMA garetosmab), but these are research references, not prescribing instructions. Any use must be under the direct supervision of a qualified physician, ideally within a clinical trial or expanded access framework.

References & further reading

PubMed: garetosmab REGN2477 fibrodysplasia ossificans progressiva LUMINA-1 Nature Medicine 2023
PubMed: REGN2477 pharmacokinetics pharmacodynamics phase 1 clinical pharmacology
PubMed: garetosmab clinical pharmacology LUMINA-1 Journal of Clinical Pharmacology 2024
ClinicalTrials.gov: OPTIMA garetosmab FOP Phase 3 Regeneron
ClinicalTrials.gov: LUMINA-1 garetosmab fibrodysplasia ossificans progressiva Phase 2